Edition:
United Kingdom

Selumetinib Granted U.S. Breakthrough Therapy Designation In Neurofibromatosis Type 1


Monday, 1 Apr 2019 

April 1 (Reuters) - Merck & Co Inc ::SELUMETINIB GRANTED U.S. BREAKTHROUGH THERAPY DESIGNATION IN NEUROFIBROMATOSIS TYPE 1.MERCK & CO INC - DESIGNATION BASED ON PHASE 2 SPRINT TRIAL IN PEDIATRIC PATIENTS WITH NF1 PLEXIFORM NEUROFIBROMAS.MERCK & CO INC - SELUMETINIB IS A MEK 1/2 INHIBITOR BEING CO-DEVELOPED BY ASTRAZENECA AND MERCK.